AI & ChatGPT searches , social queriess for CEMIPLIMAB
Search references for CEMIPLIMAB. Phrases containing CEMIPLIMAB
See searches and references containing CEMIPLIMAB!
Search references for CEMIPLIMAB. Phrases containing CEMIPLIMAB
See searches and references containing CEMIPLIMAB!CEMIPLIMAB
Pharmaceutical drug
Cemiplimab, sold under the brand name Libtayo, is a monoclonal antibody medication used for the treatment of squamous cell skin cancer. Cemiplimab belongs
Cemiplimab
Class of anticancer drugs
squamous cell lung cancer, renal cell carcinoma, and Hodgkin's lymphoma. Cemiplimab (Libtayo) was developed by Regeneron Pharmaceuticals and first approved
PD-1_and_PD-L1_inhibitors
American biotechnology company
$650 million from the development of REGN2810. REGN2810 was later named cemiplimab. In 2019, Regeneron Pharmaceuticals was announced the 7th best publicly
Regeneron_Pharmaceuticals
Anticancer medication
PD-L1 inhibitors PD-1 inhibitorsTooltip Programmed cell death protein 1 Cemiplimab Dostarlimab Nivolumab Pembrolizumab Penpulimab Retifanlimab Toripalimab
Nivolumab
Pharmaceutical drug used in cancer treatment
PD-L1 inhibitors PD-1 inhibitorsTooltip Programmed cell death protein 1 Cemiplimab Dostarlimab Nivolumab Pembrolizumab Penpulimab Retifanlimab Toripalimab
Pembrolizumab
Formulary by the World Health Organization
) / microsatellite instability-high (MSI-H) tumours Atezolizumab and cemiplimab are alternatives, including quality-assured biosimilars Nivolumab is an
WHO Model List of Essential Medicines
WHO_Model_List_of_Essential_Medicines
Anti-tumour drug
PD-L1 inhibitors PD-1 inhibitorsTooltip Programmed cell death protein 1 Cemiplimab Dostarlimab Nivolumab Pembrolizumab Penpulimab Retifanlimab Toripalimab
BMS-202
French multinational pharmaceutical and healthcare company
blood tests, lung and prostate cancer, marketed by Regeneron. Libtayo (Cemiplimab), for squamous cell skin cancer, marketed by Regeneron. Mozobil (Plerixafor)
Sanofi
Cancer arising from the cervix
Two other immune checkpoint inhibitors are used for cervical cancer: cemiplimab (Libtayo), for people with recurrent cancer after prior systemic treatment
Cervical_cancer
Medication for endometrial cancer treatment
lymphoma, renal cell carcinoma, and breast cancer. Another PD-1 antibody is cemiplimab (Libtayo) which was approved for treatment of squamous cell carcinoma
Dostarlimab
Monoclonal antibody
Avdoralimab Belimumab Bleselumab Brodalumab Camidanlumab tesirine Carlumab Cemiplimab Dupilumab Eldelumab Emapalumab Fresolimumab Garadacimab Golimumab Ianalumab†
Theralizumab
Combination medication
PD-L1 inhibitors PD-1 inhibitorsTooltip Programmed cell death protein 1 Cemiplimab Dostarlimab Nivolumab Pembrolizumab Penpulimab Retifanlimab Toripalimab
Pembrolizumab/berahyaluronidase alfa
Pembrolizumab/berahyaluronidase_alfa
Medication
PD-L1 inhibitors PD-1 inhibitorsTooltip Programmed cell death protein 1 Cemiplimab Dostarlimab Nivolumab Pembrolizumab Penpulimab Retifanlimab Toripalimab
Nivolumab/hyaluronidase
Medication
(+hyaluronidase) Avelumab Axatilimab Belantamab mafodotin Bermekimab Blinatumomab Cemiplimab Cosibelimab Daratumumab Dinutuximab beta Dostarlimab Durvalumab Elotuzumab
Elranatamab
Medication
PD-L1 inhibitors PD-1 inhibitorsTooltip Programmed cell death protein 1 Cemiplimab Dostarlimab Nivolumab Pembrolizumab Penpulimab Retifanlimab Toripalimab
Toripalimab
Medication
PD-L1 inhibitors PD-1 inhibitorsTooltip Programmed cell death protein 1 Cemiplimab Dostarlimab Nivolumab Pembrolizumab Penpulimab Retifanlimab Toripalimab
Retifanlimab
Cancer medication
PD-L1 inhibitors PD-1 inhibitorsTooltip Programmed cell death protein 1 Cemiplimab Dostarlimab Nivolumab Pembrolizumab Penpulimab Retifanlimab Toripalimab
Avelumab
Medical condition involving uncontrolled growth of skin cells
include biologic immunotherapy agents ipilimumab, pembrolizumab, nivolumab, cemiplimab; BRAF inhibitors, such as vemurafenib and dabrafenib; and a MEK inhibitor
Skin_cancer
Monoclonal antibody
PD-L1 inhibitors PD-1 inhibitorsTooltip Programmed cell death protein 1 Cemiplimab Dostarlimab Nivolumab Pembrolizumab Penpulimab Retifanlimab Toripalimab
Penpulimab
Pharmaceutical drug
PD-L1 inhibitors PD-1 inhibitorsTooltip Programmed cell death protein 1 Cemiplimab Dostarlimab Nivolumab Pembrolizumab Penpulimab Retifanlimab Toripalimab
Durvalumab
Form of cancer immunotherapy
non-small cell lung cancer, small cell lung cancer, biliary tract cancer Cemiplimab Libtayo Regeneron PD-1 2018 squamous cell carcinoma, basal cell carcinoma
Checkpoint_inhibitor
Monoclonal anti-PD-L1 antibody
PD-L1 inhibitors PD-1 inhibitorsTooltip Programmed cell death protein 1 Cemiplimab Dostarlimab Nivolumab Pembrolizumab Penpulimab Retifanlimab Toripalimab
Atezolizumab
Pharmaceutical drug classification
Pembrolizumab L01FF03 Durvalumab L01FF04 Avelumab L01FF05 Atezolizumab L01FF06 Cemiplimab L01FF07 Dostarlimab L01FF08 Prolgolimab L01FF09 Tislelizumab L01FF10 Retifanlimab
ATC_code_L01
Pharmaceutical compound
PD-L1 inhibitors PD-1 inhibitorsTooltip Programmed cell death protein 1 Cemiplimab Dostarlimab Nivolumab Pembrolizumab Penpulimab Retifanlimab Toripalimab
CA-170
prevention of organ transplant rejections, treatment of autoimmune diseases Cemiplimab Libtayo mab human PD-1 Y cutaneous squamous cell carcinoma Cergutuzumab
List of therapeutic monoclonal antibodies
List_of_therapeutic_monoclonal_antibodies
Biotechnology company in Chicago, Illinois
placement. A phase II THIO-101 clinical trial of THIO sequenced with cemiplimab to treat advanced non-small cell lung cancer (NSCLC) continued in 2024
Maia_Biotechnology
Monoclonal antibody
(+hyaluronidase) Avelumab Axatilimab Belantamab mafodotin Bermekimab Blinatumomab Cemiplimab Cosibelimab Daratumumab Dinutuximab beta Dostarlimab Durvalumab Elotuzumab
Mosunetuzumab
Form of immunotherapy
2018 – CCR4 Moxetumomab pasudotox – Lumoxiti – September 2018 – CD22 Cemiplimab – Libtayo – September 2018 – PD-1 Polatuzumab vedotin – Polivy – June
Monoclonal_antibody_therapy
combination study with Pexa-Vec and Regeneron's immune checkpoint inhibitor cemiplimab for renal cell carcinoma. In July 2017, SillaJen received approval from
SillaJen
neurotrophic keratitis Lanadelumab Takeda Pharmaceuticals hereditary angioedema Cemiplimab Regeneron Pharmaceuticals cutaneous squamous cell carcinoma Amikacin liposome
List of drugs granted breakthrough therapy designation
List_of_drugs_granted_breakthrough_therapy_designation
Monoclonal antibody
Avdoralimab Belimumab Bleselumab Brodalumab Camidanlumab tesirine Carlumab Cemiplimab Dupilumab Eldelumab Emapalumab Fresolimumab Garadacimab Golimumab Ianalumab†
Spartalizumab
Pharmaceutical compound
and pharmacodynamic activity with the oral ERAP1 inhibitor GRWD5769 and cemiplimab in 6 completed phase 1b expansion cohorts in solid tumors with anti–PD-1
GRWD5769
EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9. This phase 3 randomized trial compared cemiplimab to investigator's choice chemotherapy in recurrent/metastatic cervical
Bradley_J._Monk
Protein-coding gene in the species Homo sapiens
monotherapy, or in combination with PD-1 immune checkpoint Inhibitor Libtayo® (cemiplimab). GRCh38: Ensembl release 89: ENSG00000164307 – Ensembl, May 2017 GRCm38:
ERAP1
CEMIPLIMAB
CEMIPLIMAB
CEMIPLIMAB
CEMIPLIMAB
Girl/Female
Arabic
Dutiful; Obedient
Girl/Female
Hindu, Indian
Name of a Classical Melody
Boy/Male
Indian, Sanskrit
With Golden Horses; The Horse of Visnu
Boy/Male
Muslim/Islamic
Lynx wild cat
Girl/Female
Hindu, Indian, Telugu
Goddess Durga
Female
Hebrew
(עֲמַלְיָה) Hebrew name AMALYA means "industrious" or "work of the Lord."Â
Girl/Female
Hindu
Goddess of Matanga, Goddess Durga
Boy/Male
Hindu, Indian
Name of a Sage
Girl/Female
Muslim
Allah mercy
Boy/Male
Muslim
King
CEMIPLIMAB
CEMIPLIMAB
CEMIPLIMAB
CEMIPLIMAB
CEMIPLIMAB